Metatrace Fdg

Fludeoxyglucose (18F), the active ingredient in Metatrace Fdg, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is used in diagnostic imaging to visualize metabolically active tissues in patients undergoing oncologic, cardiac, or neurologic PET scans.

GNH USA supplies Metatrace Fdg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and clinics worldwide.

Metatrace Fdg, a fluorodeoxyglucose radiotracer, is employed in PET imaging to assess metabolic activity in various clinical settings. - Oncologic PET imaging: enables tumor detection, staging, and treatment monitoring by highlighting areas of increased glucose metabolism. - Cardiac PET imaging: assesses myocardial viability and perfusion by visualizing glucose uptake in heart muscle. - Neurologic PET imaging: aids evaluation of epilepsy and dementia by detecting abnormal cerebral glucose metabolism.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Transient flushing: brief warmth or redness. - Mild headache: short‑lasting headache after injection. - Warm sensation: temporary feeling of warmth. - Mild fatigue: short‑term tiredness.

Serious or Rare Side Effects: - Allergic reaction: includes rash, itching, or anaphylaxis. - Severe hypoglycemia: low blood sugar, especially in diabetic patients. - Radiation‑induced tissue injury: rare but possible with high cumulative exposure. - Pregnancy exposure risk: potential fetal radiation dose. - Nephrogenic toxicity: rare kidney impairment. - Severe hypotension: sudden drop in blood pressure.

Precautions should be observed before and after administration of Metatrace Fdg. - Pregnancy: avoid unless clearly needed; fetal risk is unknown. - Breastfeeding: discontinue nursing or consider alternative imaging. - Diabetes: high blood glucose may affect image quality; consider glucose control. - Renal impairment: monitor because excretion may be altered. - Radiation safety: follow institutional protocols to limit exposure to staff and patient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions must be reviewed prior to use. Major Interactions (Avoid): - High glucose intake: oral glucose or dextrose solutions shortly before the scan can reduce tracer uptake. - Insulin therapy: may alter FDG distribution; timing adjustments are required. - Iodinated contrast agents: administration within 24 hours may affect image quality. Moderate Interactions (Monitor Closely): - Metformin and other glucose‑lowering agents: may need temporary discontinuation to avoid altered uptake. - Beta‑blockers: can influence myocardial FDG uptake. - Corticosteroids: may modify inflammatory tissue uptake.